Share This Article:

Rational Usage of Disease Modifying Anti-Rheumatic Drugs with the Guidance of EULAR and ACR Suggestions

Abstract Full-Text HTML XML Download Download as PDF (Size:337KB) PP. 104-112
DOI: 10.4236/ojra.2015.54017    3,156 Downloads   3,579 Views  

ABSTRACT

Disease modifying anti-rheumatic agents are the cornerstone in management of Rheumatoid Arthritis and when used correctly they are life-saving. As the number of the agents increases, detailed guidelines become more and more important for clinicians to set safe and effective regimens. Herein, we combined the EULAR and ACR recommendations for clinicians and also pointed some important facts peculiar to our country.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Örnek, Z. , Işık, M. , Yeşil, N. , Doğan, İ. , Şahin, H. and Baki, A. (2015) Rational Usage of Disease Modifying Anti-Rheumatic Drugs with the Guidance of EULAR and ACR Suggestions. Open Journal of Rheumatology and Autoimmune Diseases, 5, 104-112. doi: 10.4236/ojra.2015.54017.

References

[1] Smolen, J.S., van der Heijde, D., Machold, K.P., et al. (2014) Proposal for a New Nomenclature of Disease-Modifying Antirheumatic Drugs. Annals of the Rheumatic Diseases, 73, 3-5.
http://dx.doi.org/10.1136/annrheumdis-2013-204317
[2] Smolen, J.S., Landewe, R., Breedveld, F.C., et al. (2010) EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs. Annals of the Rheumatic Diseases, 69, 964-975. http://dx.doi.org/10.1136/ard.2009.126532
[3] Smolen, J.S., Landewé, R., Breedveld, F.C., Buch, M., Burmester, G., Dougados, M., et al. (2014) EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2013 Update. Annals of the Rheumatic Diseases, 73, 492-509. http://dx.doi.org/10.1136/annrheumdis-2013-204573
[4] Saag, K.G., Teng, G.G., Patkar, N.M., Anuntiyo, J., Finney, C., Curtis, J.R., Paulus, H.E., Mudano, A., Pisu, M., Elkins-Melton, M., Outman, R., Allison, J.J., Suarez Almazor, M., Bridges Jr., S.L., Chatham, W.W., Hochberg, M., MacLean, C., Mikuls, T., Moreland, L.W., O’Dell, J., Turkiewicz, A.M. and Furst, D.E., American College of Rheumatology (2008) American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis & Rheumatology, 59, 762-784. http://dx.doi.org/10.1002/art.23721
[5] Singh, J.A., Furst, D.E., Bharat, A., Curtis, J.R., Kavanaugh, A.F., Kremer, J.M., Moreland, L.W., O’Dell, J., Winthrop, K.L., Beukelman, T., Bridges Jr., S.L., Chatham, W.W., Paulus, H.E., Suarez-Almazor, M., Bombardier, C., Dougados, M., Khanna, D., King, C.M., Leong, A.L., Matteson, E.L., Schousboe, J.T., Moynihan, E., Kolba, K.S., Jain, A., Volk- mann, E.R., Agrawal, H., Bae, S., Mudano, A.S., Patkar, N.M. and Saag, K.G. (2012) 2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthritis Care & Research (Hoboken), 64, 625-639.
http://dx.doi.org/10.1002/acr.21641
[6] Radner, H., Neogi, T., Smolen, J.S., et al. (2014) Performance of the 2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis: A Systematic Literature Review. Annals of the Rheumatic Diseases, 73, 114-123. http://dx.doi.org/10.1136/annrheumdis-2013-203284
[7] Smolen, J.S., Aletaha, D., Bijlsma, J.W.J., et al. (2010) Treating Rheumatoid Arthritis to Target: Recommendations of an International Task Force. Annals of the Rheumatic Diseases, 69, 631-637.
http://dx.doi.org/10.1136/ard.2009.123919
[8] Felson, D.T., Smolen, J.S., Wells, G., et al. (2011) American College of Rheumatology/European League against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. Annals of the Rheumatic Diseases, 70, 404-413. http://dx.doi.org/10.1136/ard.2011.149765
[9] Kavanaugh, A., Fleischmann, R.M., Emery, P., et al. (2013) Clinical, Functional and Radiographic Consequences of Achieving Stable Low Disease Activity and Remission with Adalimumab plus Methotrexate or Methotrexate Alone in Early Rheumatoid Arthritis: 26-Week Results from the Randomised, Controlled OPTIMA Study. Annals of the Rheumatic Diseases, 72, 64-71.
http://dx.doi.org/10.1136/annrheumdis-2011-201247
[10] Gabay, C., Emery, P., van, V.R., et al. (2013) Tocilizumab Monotherapy versus Adalimumab Monotherapy for Treat- ment of Rheumatoid Arthritis (ADACTA): A Randomised, Double-Blind, Controlled Phase 4 Trial. Lancet, 381, 1541- 1550.
http://dx.doi.org/10.1016/S0140-6736(13)60250-0
[11] Mierau, M., Schoels, M., Gonda, G., Fuchs, J., Aletaha, D. and Smolen, J.S. (2007) Assessing Remission in Clinical Practice. Rheumatology, 46, 975-979. http://dx.doi.org/10.1093/rheumatology/kem007
[12] Klarenbeek, N.B., Koevoets, R., Van der Heijde, D.M., Gerards, A.H., ten Wolde, S., Kerstens, P.J.S.M., et al. (2011) Association with Joint Damage and Physical Functioning of Nine Composite Indices and the 2011 ACR/EULAR Remission Criteria in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 70, 1815-1821. http://dx.doi.org/10.1136/ard.2010.149260
[13] Koevoets, R. and van der Heijde, D. (2009) Being in Remission or in Low Disease Activity in Rheumatoid Arthritis: Different Meaning with the Use of Different Composite Scores. Arthritis & Rheumatism, 60, 957.
[14] Smolen, J.S., Han, C., Van der Heijde, D.M., Emery, P., Bathon, J.M., Keystone, E., et al. (2009) Radiographic Changes in Rheumatoid Arthritis Patients Attaining Different Disease Activity States with Methotrexate Monotherapy and Infliximab plus Methotrexate: The Impacts of Remission and TNF-Blockade. Annals of the Rheumatic Diseases, 68, 823-827.
http://dx.doi.org/10.1136/ard.2008.090019
[15] Aletaha, D., Funovits, J., Keystone, E.C. and Smolen, J.S. (2007) Disease Activity Early in the Course of Treatment Predicts Response to Therapy after One Year in Rheumatoid Arthritis Patients. Arthritis & Rheumatism, 56, 3226-3235. http://dx.doi.org/10.1002/art.22943
[16] Visser, K. and van der Heijde, D. (2009) Optimal Dosage and Route of Administration of Methotrexate in Rheumatoid Arthritis: A Systematic Review of the Literature. Annals of the Rheumatic Diseases, 68, 1094-1099. http://dx.doi.org/10.1136/ard.2008.092668
[17] Aletaha, D., Martinez-Avila, J., Kvien, T.K. and Smolen, J.S. (2012) Definition of Treatment Response in Rheumatoid Arthritis Based on the Simplified and the Clinical Disease Activity Index. Annals of the Rheumatic Diseases, 71, 1190- 1196. http://dx.doi.org/10.1136/annrheumdis-2012-201491
[18] van Gestel, A.M., Haagsma, C.J. and van Riel, P.L.C.M. (1998) Validation of Rheumatoid Arthritis Improvement Criteria That Include Simplified Joint Counts. Arthritis & Rheumatism, 41, 1845-1850.
http://dx.doi.org/10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K
[19] Pincus, T., Yazici, Y., Sokka, T., Aletaha, D. and Smolen, J.S. (2003) Methotrexate as the “Anchor Drug” for the Treatment of Early Rheumatoid Arthritis. Clinical and Experimental Rheumatology, 21, S178-S185.
[20] Aletaha, D., Funovits, J. and Smolen, J.S. (2008) The Importance of Reporting Disease Activity States in Clinical Trials of Rheumatoid Arthritis. Arthritis & Rheumatism, 58, 2622-2631.
http://dx.doi.org/10.1002/art.23733
[21] Breedveld, F.C., Weisman, M.H., Kavanaugh, A.F., Cohen, S.B., Pavelka, K., van Vollenhoven, R., et al. (2006) The PREMIER Study—A Multicenter, Randomized, Double-Blind Clinical Trial of Combination Therapy with Adalimu- mab plus Methotrexate versus Methotrexate Alone or Adalimumab Alone in Patients with Early, Aggressive Rheu- matoid Arthritis Who Had Not Had Previous Methotrexate Treatment. Arthritis & Rheumatism, 54, 26-37. http://dx.doi.org/10.1002/art.21519
[22] St Clair, E.W., van der Heijde, D.M., Smolen, J.S., Maini, R.N., Bathon, J.M., Emery, P., et al. (2004) Combination of Infliximab and Methotrexate Therapy for Early Rheumatoid Arthritis: A Randomized, Controlled Trial. Arthritis & Rheumatism, 50, 3432-3443. http://dx.doi.org/10.1002/art.20568
[23] Klareskog, L., van der Heijde, D., de Jager, J.P., Gough, A., Kalden, J., Malaise, M., et al. (2004) Therapeutic Effect of the Combination of Etanercept and Methotrexate Compared with Each Treatment Alone in Patients with Rheumatoid Arthritis: Double-Blind Randomised Controlled Trial. Lancet, 363, 675-681. http://dx.doi.org/10.1016/S0140-6736(04)15640-7
[24] Tak, P.P., Rigby, W.F., Rubbert-Roth, A., Peterfy, C.G., van Vollenhoven, R.F., Stohl, W., et al. (2011) Inhibition of Joint Damage and Improved Clinical Outcomes with Rituximab plus Methotrexate in Early Active Rheumatoid Arthritis: The IMAGE Trial. Annals of the Rheumatic Diseases, 70, 39-46. http://dx.doi.org/10.1136/ard.2010.137703
[25] Westhovens, R., Robles, M., Ximenes, A.C., Nayiager, S., Wollenhaupt, J., Durez, P., et al. (2009) Clinical Efficacy and Safety of Abatacept in Methotrexate-Naive Patients with Early Rheumatoid Arthritis and Poor Prognostic Factors. Annals of the Rheumatic Diseases, 68, 1870-1877.
http://dx.doi.org/10.1136/ard.2008.101121
[26] Heimans, L., Wevers-de Boer, K.V., Visser, K., Goekoop, R.J., van Oosterhout, M., Harbers, J.B., et al. (2013) A Two-Step Treatment Strategy Trial in Patients with Early Arthritis Aimed at Achieving Remission: The IMPROVED Study. Annals of the Rheumatic Diseases, 73, 1356-1361.
http://dx.doi.org/10.1136/annrheumdis-2013-203243
[27] van der Heijde, D.M., van Riel, P.L., Gribnau, F.W., Nuver-Zwart, I.H. and Van De Putte, L.B. (1989) Effects of Hydroxychloroquine and Sulphasalazine on Progression of Joint Damage in Rheumatoid Arthritis. Lancet, 333, 1036- 1038. http://dx.doi.org/10.1016/S0140-6736(89)92442-2
[28] Smolen, J.S., Kalden, J.R., Scott, D.L., Rozman, B., Kvien, T.K., Larsen, A., et al. (1999) Efficacy and Safety of Leflunomide Compared with Placebo and Sulphasalazine in Active Rheumatoid Arthritis: A Double-Blind, Ran- domised, Multicentre Trial. Lancet, 353, 259-266.
http://dx.doi.org/10.1016/S0140-6736(98)09403-3
[29] Sharp, J.T., Strand, V., Leung, H., Hurley, F. and Loew-Friedrich, I. (2000) Treatment with Leflunomide Slows Radiographic Progression of Rheumatoid Arthritis. Results from Three Randomized Controlled Trials of Leflunomide in Patients with Active Rheumatoid Arthritis. Arthritis & Rheumatism, 43, 495-505. http://dx.doi.org/10.1002/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U
[30] Strand, V., Cohen, S., Schiff, M., Weaver, A., Fleischmann, R., Cannon, G., et al. (1999) Treatment of Active Rheu- matoid Arthritis with Leflunomide Compared with Placebo and Methotrexate. Archives of Internal Medicine, 159, 2542-2550. http://dx.doi.org/10.1001/archinte.159.21.2542
[31] Dougados, M., Combe, B., Cantagrel, A., Goupille, P., Olive, P., Schattenkirchner, M., et al. (1999) Combination Therapy in Early Rheumatoid Arthritis: A Randomised, Controlled, Double Blind 52 Week Clinical Trial of Sulpha- salazine and Methotrexate Compared with the Single Components. Annals of the Rheumatic Diseases, 58, 220-225.
http://dx.doi.org/10.1136/ard.58.4.220
[32] Burmester, G.R., Mariette, X., Montecucco, C., Monteagudo-Sáez, I., Malaise, M., Tzioufas, A.G., et al. (2007) Adali- mumab Alone and in Combination with Disease-Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis in Clinical Practice: The Research in Active Rheumatoid Arthritis (ReAct) Trial. Annals of the Rheumatic Diseases, 66, 732-739.
http://dx.doi.org/10.1136/ard.2006.066761
[33] Strangfeld, A., Hierse, F., Kekow, J., von Hinueber, U., Tony, H.-P., Dockhorn, R., et al. (2009) Comparative Effectiveness of Tumour Necrosis Factor Alpha Inhibitors in Combination with either Methotrexate or Leflunomide. Annals of the Rheumatic Diseases, 68, 1856-1862.
http://dx.doi.org/10.1136/ard.2008.098467
[34] van Vollenhoven, R.F., Geborek, P., Forslind, K., Albertsson, K., Ernestam, S., Petersson, I.F., et al. (2012) Conven- tional Combination Treatment versus Biological Treatment in Methotrexate-Refractory Early Rheumatoid Arthritis: 2 Year Follow-Up of the Randomised, Non-Blinded, Parallel-Group Swefot Trial. Lancet, 379, 1712-1720. http://dx.doi.org/10.1016/S0140-6736(12)60027-0
[35] de Jong, P.H., Hazes, J.M., Barendregt, P.J., Huisman, M., van Zeben, D., van der Lubbe, P.A., et al. (2013) Induction Therapy with a Combination of DMARDs Is Better than Methotrexate Monotherapy: First Results of the tREACH Trial. Annals of the Rheumatic Diseases, 72, 72-78.
http://dx.doi.org/10.1136/annrheumdis-2011-201162
[36] Moreland, L.W., O’Dell, J.R., Paulus, H.E., Curtis, J.R., Bathon, J.M., St. Clair, E.W., et al. (2012) A Randomized Comparative Effectiveness Study of Oral Triple Therapy versus Etanercept plus Methotrexate in Early Aggressive Rheumatoid Arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis & Rheumatism, 64, 2824-2835.
http://dx.doi.org/10.1002/art.34498
[37] Leirisalo-Repo, M., Kautiainen, H., Laasonen, L., Korpela, M., Kauppi, M.J., Kaipiainen-Seppänen, O., et al. (2013) Infliximab for 6 Months Added on Combination Therapy in Early Rheumatoid Arthritis: 2-Year Results from an Investigator-Initiated, Randomised, Double-Blind, Placebo-Controlled Study (the NEO-RACo Study). Annals of the Rheumatic Diseases, 72, 851-857.
http://dx.doi.org/10.1136/annrheumdis-2012-201365
[38] O’Dell, J.R., Mikuls, T.R., Taylor, T.H., Ahluwalia, V., Brophy, M., Warren, S.R., et al. (2013) Therapies for Active Rheumatoid Arthritis after Methotrexate Failure. New England Journal of Medicine, 369, 307-318. http://dx.doi.org/10.1056/NEJMoa1303006
[39] Klarenbeek, N.B., Guler-Yuksel, M., van der Kooij, S.M., Han, K.H., Ronday, H.K., Kerstens, P.J.S.M., et al. (2011) The Impact of Four Dynamic, Goal-Steered Treatment Strategies on the 5-Year Outcomes of Rheumatoid Arthritis Patients in the BeSt Study. Annals of the Rheumatic Diseases, 70, 1039-1046.
http://dx.doi.org/10.1136/ard.2010.141234
[40] De Jong, P.H.P.D., Hazes, J.M., Luime, J.J. and Weel, A.E. (2013) Randomized Comparison of Triple DMARD Therapy with Methotrexate Mono-Therapy. Annals of the Rheumatic Diseases, 72, A113.
http://dx.doi.org/10.1136/annrheumdis-2013-eular.382
[41] Bakker, M.F., Jacobs, J.W., Welsing, P.M., Verstappen, S.M.M., Tekstra, J., Ton, E., et al. (2012) Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis: A Randomized Trial. Annals of Internal Medicine, 156, 329-339.
http://dx.doi.org/10.7326/0003-4819-156-5-201203060-00004
[42] Buttgereit, F., da Silva, J.A., Boers, M., Burmester, G.-R., Cutolo, M., Jacobs, J., et al. (2002) Standardised Nomenclature for Glucocorticoid Dosages and Glucocorticoid Treatment Regimens: Current Questions and Tentative Answers in Rheumatology. Annals of the Rheumatic Diseases, 61, 718-722. http://dx.doi.org/10.1136/ard.61.8.718
[43] Svensson, B., Boonen, A., Albertsson, K., van der Heijde, D., Keller, C., Hafström, I., et al. (2005) Low-Dose Prednisolone in Addition to the Initial Disease-Modifying Antirheumatic Drug in Patients with Early Active Rheu- matoid Arthritis Reduces Joint Destruction and Increases the Remission Rate: A Two-Year Randomized Trial. Arthritis & Rheumatism, 52, 3360-3370.
http://dx.doi.org/10.1002/art.21298
[44] Landewe, R.B., Boers, M., Verhoeven, A.C., Westhovens, R., van de Laar, M.A.F.J., Markusse, H.M., et al. (2002) COBRA Combination Therapy in Patients with Early Rheumatoid Arthritis: Long-Term Structural Benefits of a Brief Intervention. Arthritis & Rheumatism, 46, 347-356.
http://dx.doi.org/10.1002/art.10083
[45] Wassenberg, S., Rau, R., Steinfeld, P., Zeidler, H. and Low-Dose Prednisolone Therapy Study Group (2005) Very Low-Dose Prednisolone in Early Rheumatoid Arthritis Retards Radiographic Progression Over Two Years: A Multi- center, Double-Blind, Placebo-Controlled Trial. Arthritis & Rheumatism, 52, 3371-3380. http://dx.doi.org/10.1002/art.21421
[46] Vastesaeger, N., Xu, S., Aletaha, D., St Clair, E.W. and Smolen, J.S. (2009) A Pilot Risk Model for the Prediction of Rapid Radiographic Progression in Rheumatoid Arthritis. Rheumatology, 48, 1114-1121. http://dx.doi.org/10.1093/rheumatology/kep155
[47] Visser, K., Goekoop-Ruiterman, Y.P., de Vries-Bouwstra, J.K., Ronday, H.K., Seys, P.E.H., Kerstens, P.J.S.M., et al. (2010) A Matrix Risk Model for the Prediction of Rapid Radiographic Progression in Patients with Rheumatoid Arthritis Receiving Different Dynamic Treatment Strategies: Post Hoc Analyses from the BeSt Study. Annals of the Rheumatic Diseases, 69, 1333-1337.
http://dx.doi.org/10.1136/ard.2009.121160
[48] Moreland, L.W., O’Dell, J.R., Paulus, H.E., et al. (2010) Two-Year Radiographic Results from the TEAR Trial. Arthritis & Rheumatism, 62, S568-S569.
[49] Weinblatt, M.E., Schiff, M., Valente, R., van der Heijde, D., Citera, G., Zhao, C., et al. (2013) Head-to-Head Com- parison of Subcutaneous Abatacept versus Adalimumab for Rheumatoid Arthritis: Findings of a Phase IIIB, Multi- national, Prospective, Randomized Study. Arthritis & Rheumatism, 65, 28-38. http://dx.doi.org/10.1002/art.37711
[50] Emery, P., Fleischmann, R., Filipowicz-Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., et al. (2006) The Efficacy and Safety of Rituximab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment: Results of a Phase IIB Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial. Arthritis & Rheumatism, 54, 1390-1400.
http://dx.doi.org/10.1002/art.21778
[51] Buch, M.H., Smolen, J.S., Betteridge, N., Breedveld, F.C., Burmester, G., Dörner, T., et al. (2011) Updated Consensus Statement on the Use of Rituximab in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 70, 909- 920. http://dx.doi.org/10.1136/ard.2010.144998
[52] Strangfeld, A., Pattloch, D., Herzer, P., Edelmann, E., Zinke, S., Aringer, M. and Listing, J. (2013) Risk of Cancer Recurrence or New Tumors in RA Patients with Prior Malignancies Treated with Various Biologic Agents. Arthritis & Rheumatism, 65, S806.
https://ww2.rheumatology.org/apps/MyAnnualMeeting/Abstract/36584
[53] Huizinga, T., Kivitz, A.J., Rell-Bakalarska, M., Fleischmann, R.M., Jasson, M., Radin, A.R. and Genovese, M.C. (2012) Sarilumab for the Treatment of Moderate-to-Severe Rheumatoid Arthritis: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, International Study. Annals of the Rheumatic Diseases, 71, 60. http://dx.doi.org/10.1136/annrheumdis-2012-eular.1706
[54] Hsu, B., Sheng, S.H., Smolen, J. and Weinblatt, M. (2011) Results from a 2-Part, Proof-of-Concept, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Sirukumab, a Human Anti-Interleukin-6 Mono- clonal Antibody, in Active Rheumatoid Arthritis Patients Despite Methotrexate Therapy. Arthritis & Rheumatism, 63, S1034.
[55] Mease, P., Strand, V., Shalamberidze, L., Dimic, A., Raskina, T., Xu, L.-A., et al. (2012) A Phase II, Double-Blind, Randomised, Placebo-Controlled Study of BMS945429 (ALD518) in Patients with Rheumatoid Arthritis with an Inadequate Response to Methotrexate. Annals of the Rheumatic Diseases, 71, 1183-1189.
http://dx.doi.org/10.1136/annrheumdis-2011-200704
[56] van Vollenhoven, R.F., Fleischmann, R., Cohen, S., Lee, E.B., Meijide, J.A.G., Wagner, S., et al. (2012) Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis. New England Journal of Medicine, 367, 508-519.
http://dx.doi.org/10.1056/NEJMoa1112072
[57] Burmester, G.R., Blanco, R., Charles-Schoeman, C., Wollenhaupt, J., Zerbini, C., Benda, B., et al. (2013) Tofacitinib (CP-690,550) in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis with an Inadequate Response to Tumour Necrosis Factor Inhibitors: A Randomised Phase 3 Trial. Lancet, 381, 451-460. http://dx.doi.org/10.1016/S0140-6736(12)61424-X
[58] Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C.A., Bradley, J.D., et al. (2012) Placebo- Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. New England Journal of Medicine, 367, 495-507.
http://dx.doi.org/10.1056/NEJMoa1109071
[59] van der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., et al. (2013) Tofacitinib (CP-690,550) in Patients with Rheumatoid Arthritis on Methotrexate: 12-Month Data from a 24-Month Phase 3 Ran- domized Radiographic Study. Arthritis & Rheumatism, 65, 559-570. http://dx.doi.org/10.1002/art.37816
[60] Tanaka, Y., Hirata, S., Saleem, B. and Emery, P. (2013) Discontinuation of Biologics in Patients with Rheumatoid Arthritis. Clinical and Experimental Rheumatology, 31, S22-S27.
[61] Kavanaugh, A. and Smolen, J.S. (2013) The When and How of Biologics Withdrawal in Rheumatoid Arthritis— Learning from Large Randomized Controlled Trials. Clinical and Experimental Rheumatology, 31, S19-S21.
[62] Tanaka, Y., Takeuchi, T., Mimori, T., Saito, K., Nawata, M., Kameda, H., et al. (2010) Discontinuation of Infliximab after Attaining Low Disease Activity in Patients with Rheumatoid Arthritis: RRR (Remission Induction by Remicade in RA) Study. Annals of the Rheumatic Diseases, 69, 1286-1291. http://dx.doi.org/10.1136/ard.2009.121491
[63] Chatzidionysiou, K., Turesson, C., Teleman, A., Knight, A., Lindqvist, E., Larsson, P., et al. (2012) A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission. Arthritis & Rheumatism, 64, S336.
[64] ten Wolde, S., Breedveld, F.C., Dijkmans, B.A.C., Hermans, J., Vandenbroucke, J.P., van de Laar, M.A.F.J., et al. (1996) Randomised Placebo-Controlled Study of Stopping Second-Line Drugs in Rheumatoid Arthritis. Lancet, 347, 347-352. http://dx.doi.org/10.1016/S0140-6736(96)90535-8
[65] O’Mahony, R., Richards, A., Deighton, C. and Scott, D. (2010) Withdrawal of DMARDs in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Annals of the Rheumatic Diseases, 69, 1823-1826. http://dx.doi.org/10.1136/ard.2008.105577
[66] van der Woude, D., Visser, K., Klarenbeek, N.B., Ronday, H.K., Peeters, A.J., Kerstens, P.J.S.M., et al. (2012) Sustained Drug-Free Remission in Rheumatoid Arthritis after DAS-Driven or Non-DAS-Driven Therapy: A Com- parison of Two Cohort Studies. Rheumatology, 51, 1120-1128.
http://dx.doi.org/10.1093/rheumatology/ker516
[67] Gonzalez, A., Maradit, K.H., Crowson, C.S., Ballman, K.V., Roger, V.L., Jacobsen, S.J., et al. (2008) Do Cardio- vascular Risk Factors Confer the Same Risk for Cardiovascular Outcomes in Rheumatoid Arthritis Patients as in Non-Rheumatoid Arthritis Patients? Annals of the Rheumatic Diseases, 67, 64-69. http://dx.doi.org/10.1136/ard.2006.059980
[68] Baecklund, E., Iliadou, A., Askling, J., Ekbom, A., Backlin, C., Granath, F., et al. (2006) Association of Chronic Inflammation, Not Its Treatment, with Increased Lymphoma Risk in Rheumatoid Arthritis. Arthritis & Rheumatism, 54, 692-701. http://dx.doi.org/10.1002/art.21675
[69] Choi, H.K., Hernan, M.A., Seeger, J.D., Robins, J.M. and Wolfe, F. (2002) Methotrexate and Mortality in Patients with Rheumatoid Arthritis: A Prospective Study. Lancet, 359, 1173-1177.
http://dx.doi.org/10.1016/S0140-6736(02)08213-2
[70] Westlake, S.L., Colebatch, A.N., Baird, J., Kiely, P., Quinn, M., Choy, E., et al. (2010) The Effect of Methotrexate on Cardiovascular Disease in Patients with Rheumatoid Arthritis: A Systematic Literatüre Review. Rheumatology, 49, 295-307. http://dx.doi.org/10.1093/rheumatology/kep366
[71] Westlake, S.L., Colebatch, A.N., Baird, J., Curzen, N., Kiely, P., Quinn, M., et al. (2011) Tumour Necrosis Factor Antagonists and the Risk of Cardiovascular Disease in Patients with Rheumatoid Arthritis: A Systematic Literature Review. Rheumatology, 50, 518-531.
http://dx.doi.org/10.1093/rheumatology/keq316

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.